查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1969272

非班太爾市場：依動物種類、製劑形式、產品類型及通路－2026-2032年全球預測

Febantel Market by Animal Type, Formulation, Product Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，非班替爾市場價值將達到 45.2 億美元，到 2026 年將成長到 47.7 億美元，到 2032 年將達到 68.6 億美元，複合年成長率為 6.12%。

主要市場統計數據
基準年 2025 45.2億美元
預計年份：2026年 47.7億美元
預測年份 2032 68.6億美元
複合年成長率 (%) 6.12%

本文全面介紹了 Febantaire 的治療特性、臨床應用以及在獸醫學領域的策略意義，將有助於決策。

非班太爾作為一種頻譜驅蟲藥，在獸醫學領域佔據著獨特的地位，其應用範圍廣泛，涵蓋伴侶動物和生產動物。其藥理特性使其常用於聯合治療，以應對損害動物健康、福利和生產力的線蟲感染。臨床醫生依賴基於非班太爾的治療方案，透過其良好的耐受性和便捷的給藥方式簡化寄生蟲管理，減少多重用藥，並提高飼主的依從性。從商業性角度來看，非班太爾的市場地位受到製劑創新、跨司法管轄區監管核准以及不斷發展的通路的影響，這些因素都會影響其覆蓋範圍和處方行為。

確定將重塑獸藥領域對非班替爾的需求、監管預期、技術採用和供應鏈韌性的變革性變化。

由於技術進步、監管調整和相關人員行為的轉變，非班替爾（febantel）的市場環境正在改變。製劑科學的創新（例如偏好的片劑和穩定的液體懸浮液）正在擴大其適用範圍，使其能夠惠及更多不同類型的患者和給藥環境。同時，數位化獸醫平台和線上零售管道的擴張正在重塑飼主獲取治療的方式，遠端醫療也正在影響處方模式和用藥依從性監測。雖然這些變化降低了產品取得的門檻，但也提高了人們對清晰標籤、便捷給藥和安全性證據的期望。

評估 2025 年美國對 Febantel 徵收的新關稅對 Febantel 供應鏈、定價策略和全球貿易流量的累積影響。

美國2025年實施的關稅政策，為與菲萬特相關的全球供應鏈和商業策略增添了新的複雜性。進口關稅及其調整後的關稅表正在影響原料採購、成品通路以及與海外合作夥伴的合約條款。因此，先前依賴跨國採購的企業被迫重新評估與供應商的關係，重新審視其到岸成本結構，並考慮近岸外包和雙重採購策略，以維持供應的連續性和價格的穩定性。

透過詳細的細分分析揭示非班特爾的使用模式：動物種類、通路、製劑形式偏好和產品類型的組合。

透過細分市場分析所揭示的細微採用模式，可為產品開發和商業性優先排序提供指南。依動物種類分類，非班替爾在伴侶動物和牲畜應用上的需求有差異。在伴侶動物領域，貓狗配方需要專注於偏好、給藥頻率和給藥便利性，以提高飼主依從性。在畜牧業領域，牛、豬、家禽和羊的需求則著重於藥物的穩健性、成本效益以及明確的停藥期指導，以滿足食品安全框架和農場實際操作的要求。

非班特爾的關鍵區域洞察：美洲、歐洲、中東和非洲以及亞太地區的差異化推動因素和戰略需求

區域趨勢顯著影響非班替爾產品開發和商業化的策略需求。在美洲，較高的寵物飼養率和一體化的動物醫藥分銷網路影響著需求模式，促使市場更加關注偏好高的處方箋製劑和電商供應模式。此外，該地區的法規結構和管控措施也凸顯了與生產動物相關的產品中，清楚標註殘留物和停藥期的重要性。

本報告從主要企業的角度，詳細分析了與非班特相關的利害關係人的競爭定位、產品系列策略、合作模式和創新軌跡。

非班太爾產業的企業層面發展趨勢正體現在產品系列策略、合作模式以及對生產能力的投資。現有製藥公司優先考慮將非班太爾與其他活性成分結合的綜合產品組合，並著重於提交監管文件和提供臨床證據以支持組合藥物的療效。同時，專業生產商和非專利生產商則專注於提升營運效率、制定具有競爭力的價格，並建立快速分銷網路，以滿足價格敏感型市場的需求，尤其是在大規模動物養殖領域。

為行業領導者提供切實可行的建議，以增強韌性、加快招聘、最佳化投資組合併應對監管和貿易逆風。

產業領導者應推動一系列切實可行的措施，以增強產品韌性和商業性影響力。首先，應優先考慮供應來源多元化，並考慮將關鍵製造地遷至近岸地區，以降低國際關稅波動和物流瓶頸帶來的風險。此外，還應透過長期供應協議中的合約機制來分散風險並穩定價格，從而完善供應多元化。

調查方法、資料來源、分析框架、檢驗程序和品管。

本分析採用結構化且透明的方法，整合了第一手和第二手研究。第一手研究包括對執業獸醫、法規事務專家、分銷主管和生產營運經理的訪談，並輔以對伴侶動物和生產動物用藥實踐的現場觀察。第二手研究收集了公開的監管文件、關於驅蟲藥療效和安全性的同行評審臨床文獻、行業期刊以及與藥品進出口趨勢相關的物流文件。

總結獸用非班特爾相關相關人員的整合工作，重點在於策略關鍵點、前瞻性考量和優先行動

這項分析強調，非班替爾仍然是獸醫寄生蟲學中一種具有重要戰略意義的治療藥物，其效用可透過合理的製劑設計、分銷策略和聯合治療進一步提升。關鍵挑戰包括：根據物種特定需求調整產品特性、加強供應鏈以應對貿易中斷，以及積極參與監管和控制框架以維持臨床療效。雖然這些優先事項在伴侶動物和生產動物領域都通用，但不同地區和通路的實施重點有所不同。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 非班太爾市場：依動物類型分類

  • 伴侶動物
    • 貓
    • 狗
  • 農場動物
    • 牛
    • 豬
    • 家禽
    • 羊

第9章：非班特爾市場（以劑型分類）

  • 液體
    • 解決方案
    • 懸浮液
  • 粉末
  • 藥片
    • 薄膜塗層
    • 未塗層

第10章 非班太爾市場：依產品類型分類

  • 組合藥物
    • 非班太爾和吡喹酮的組合藥物
    • 非班太爾和吡喹酮的組合藥物
  • 單藥治療

第11章 非班太爾市場：依分銷管道分類

  • 線上零售商
    • 直接電子商務
    • 市場
  • 藥局
  • 動物醫院

第12章 非班太爾市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 菲班特市場：依集團分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 非班太爾市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國非班太爾市場

第16章：中國非班太爾市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alivira Animal Health Limited
  • Angle Bio Pharma
  • Jigs Chemical Limited
  • Niksan Pharmaceutical
  • Omshri Labs Pvt Ltd.
  • Pranshav Health Care
  • Pure Chem Pvt. Ltd.
  • Raxuter Chemicals
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Shreeji Pharma International
Product Code: MRR-535C6291879E

The Febantel Market was valued at USD 4.52 billion in 2025 and is projected to grow to USD 4.77 billion in 2026, with a CAGR of 6.12%, reaching USD 6.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.52 billion
Estimated Year [2026] USD 4.77 billion
Forecast Year [2032] USD 6.86 billion
CAGR (%) 6.12%

Comprehensive introduction to Febantel's therapeutic profile, clinical applications, and strategic relevance across veterinary sectors to inform decision-making

Febantel occupies a distinct position within veterinary therapeutics as a broad-spectrum anthelmintic with applications spanning both companion and production animals. Its pharmacological profile, often leveraged in combination therapies, addresses nematode burdens that compromise animal health, welfare, and productivity. Clinicians rely on febantel-based regimens to simplify parasite control, reduce polypharmacy, and enhance owner compliance through tolerability and dosing convenience. From a commercial vantage, febantel's role is shaped by formulation innovation, regulatory approvals across jurisdictions, and evolving distribution pathways that affect reach and prescribing behavior.

Transitioning from the clinical to the commercial domain requires an appreciation of how febantel interacts with emerging trends in animal health. For example, the drive toward integrated parasitic control programs, heightened attention to resistance management, and the expansion of veterinary services in digital channels all influence formulation preferences and procurement patterns. Moreover, regulatory scrutiny around drug residues, withdrawal periods for production animals, and product safety remains a persistent design constraint for developers and manufacturers. Accordingly, stakeholders must balance therapeutic efficacy with manufacturability, supply chain resilience, and compliance to maintain product relevance and trust among veterinarians and producers.

In sum, a holistic introduction to febantel should synthesize its clinical utility, formulation considerations, and the external forces shaping its demand trajectory. By doing so, organizations can better align R&D, regulatory, and commercial strategies to the real-world contexts in which febantel-based interventions deliver value.

Identification of transformative shifts reshaping Febantel demand, regulatory expectations, technological adoption, and supply chain resilience across animal health

The landscape for febantel is undergoing transformative shifts driven by technological advances, regulatory realignment, and changing stakeholder behaviors. Innovations in formulation science, including palatable tablets and stabilized liquid suspensions, enable broader adoption across diverse patient types and administration settings. Simultaneously, digital veterinary platforms and the expansion of online retail channels reshape how owners access therapies, while telemedicine influences prescribing patterns and adherence monitoring. These shifts reduce friction in product access but also elevate expectations for clear labeling, dosing convenience, and evidence of safety.

Regulatory evolution and antimicrobial stewardship initiatives are also prompting reassessments of parasiticide use. Increasing emphasis on integrated parasite management and resistance surveillance encourages combination therapies and strategic rotation of active ingredients. Consequently, manufacturers are adapting portfolios to emphasize combinations that address multi-parasite burdens, thereby preserving efficacy and extending clinical lifespans of key actives. At the same time, supply chain transparency and traceability are becoming competitive differentiators, with organizations investing in supplier validation, alternate sourcing, and inventory analytics to mitigate disruption risks and ensure continuity for both companion and farm animal customers.

Taken together, these transformative dynamics require organizations to reexamine product positioning, engage more proactively with regulatory stakeholders, and accelerate digital and operational investments. Those that anticipate and align with these shifts will secure stronger clinician trust, maintain market access, and unlock new channels of growth across veterinary care segments.

Assessment of the cumulative impact of newly imposed United States tariffs in 2025 on Febantel supply chains, pricing strategies, and global trade flows

The introduction of tariffs in the United States during 2025 has added a layer of complexity for global supply chains and commercial strategies related to febantel. Import duties and adjusted tariff schedules influence raw material sourcing, finished product routing, and contractual terms with overseas partners. As a result, organizations that historically relied on cross-border procurement have had to revisit supplier relationships, reassess landed cost structures, and consider nearshoring or dual-sourcing approaches to preserve supply continuity and price stability.

At the same time, tariff-driven cost pressures have altered pricing negotiations and promotional strategies. Veterinary distributors and clinics, operating on tight margin structures, face a choice between absorbing increased procurement costs or passing them along to end customers, which affects adoption in price-sensitive segments. Additionally, tariffs interact with regulatory constraints-such as labeling, packaging, and residue testing requirements-creating operational hurdles for companies that must navigate both trade compliance and product integrity obligations. This convergence has incentivized more collaborative commercial models, including longer-term supply contracts, risk-sharing clauses, and indexed pricing mechanisms to distribute exposure across the value chain.

Ultimately, the cumulative impact of the 2025 tariff environment underscores the importance of agility in sourcing, disciplined cost management, and strengthened stakeholder collaboration. Organizations that proactively model tariff scenarios, diversify sourcing footprints, and streamline logistics will better preserve therapeutic availability and sustain clinical trust among veterinarians and animal owners.

In-depth segmentation insights revealing adoption patterns by animal type, distribution channel, formulation preferences, and product type combinations for Febantel

Segmentation reveals nuanced adoption patterns that inform product development and commercial prioritization. When viewed by animal type, febantel demonstrates differentiated demand between companion animal use and farm animal applications. Within the companion segment, formulations tailored to cats and dogs must address palatability, dosing frequency, and ease of administration to drive adherence among owners. In the production animal space, the requirements for cattle, pigs, poultry, and sheep emphasize robustness, cost-efficiency, and clear withdrawal guidance to meet food safety frameworks and on-farm operational realities.

Distribution channel dynamics further shape access and purchasing behavior. Online retailers, which encompass direct ecommerce and marketplace models, have expanded reach and convenience but require rigorous cold chain and compliance capabilities for pharmaceuticals. Pharmacies continue to serve as trusted points for over-the-counter access and pharmacist counseling, while veterinary clinics remain central to prescription-led use and clinical guidance. Each channel demands distinct packaging, labeling, and promotional strategies to align with buyer expectations and regulatory boundaries.

Formulation choices influence clinical uptake and logistical considerations. Liquid presentations, including solutions and suspensions, are valued for dosing flexibility and use in species where precise adjustments are necessary, whereas powder forms offer cost-effective dosing for group treatments. Tablets, available in film coated and uncoated formats, provide stability and ease of distribution for companion applications. Product type distinctions between monotherapy and combination offerings are pivotal, with combination products-such as febantel paired with praziquantel or febantel paired with pyrantel-addressing multiple parasite classes and simplifying control programs, thereby increasing appeal among practitioners focused on integrated parasitic management.

Taken together, these segmentation insights guide prioritization across R&D, commercial routing, and supply chain design, enabling organizations to tailor interventions to the unique demands of species, distribution channels, formulations, and combination strategies.

Key regional insights illustrating differential drivers and tactical imperatives across the Americas, Europe, Middle East & Africa, and the Asia-Pacific for Febantel

Regional dynamics materially shape strategic imperatives for febantel product development and commercialization. In the Americas, demand patterns are influenced by large companion animal ownership rates and consolidated veterinary distribution networks, driving focus on palatable, clinic-prescribed formulations as well as e-commerce fulfillment models. Regulatory frameworks and stewardship programs in this region also elevate the importance of clear residue and withdrawal labeling for products that intersect production animal use.

Across Europe, the Middle East & Africa, stakeholders confront a diverse regulatory landscape and heterogenous veterinary infrastructure. In parts of Europe, stringent regulatory oversight and established resistance monitoring encourage combination therapies and stewardship-aligned deployment. Conversely, markets within the Middle East & Africa may prioritize affordability and operational practicality for cattle, sheep, and poultry applications, necessitating formulations and packaging that align with on-farm realities and local supply chain limitations. These contrasts demand flexible commercial approaches that balance regulatory compliance with pragmatic delivery models.

The Asia-Pacific region presents a constellation of rapid demand evolution, driven by intensifying livestock production systems and expanding companion animal ownership in urban centers. This dynamic environment rewards manufacturers that can scale production efficiently, adapt labeling to multiple regulatory regimes, and deploy targeted sales channels to reach both modern retail networks and traditional veterinary suppliers. Across regions, tailored regulatory strategies, logistics optimization, and culturally attuned commercial messaging are essential for sustained product uptake and reputational strength.

Key company-level insights detailing competitive positioning, portfolio strategies, collaboration patterns, and innovation trajectories among Febantel stakeholders

Company-level behavior in the febantel space manifests through portfolio strategies, collaboration models, and investment in manufacturing capabilities. Established pharmaceutical entities prioritize integrated portfolios that combine febantel with complementary actives, emphasizing regulatory dossiers and clinical evidence to support combination claims. Conversely, specialized manufacturers and generic producers focus on operational efficiencies, competitive pricing, and rapid distribution to serve price-sensitive segments, particularly in large-scale production animal contexts.

Partnerships and contract manufacturing relationships have become central to ensuring supply continuity and flexibility. Strategic alliances between innovators and regional distributors facilitate regulatory navigation and market entry, while co-development agreements enable the pairing of febantel with other actives to meet clinical demand for broad-spectrum control. Investment in quality management systems and certification for good manufacturing practices is a consistent differentiator, particularly for companies exporting to multiple jurisdictions with varying compliance expectations.

Innovation trajectories include formulation refinement to improve palatability and dosing accuracy, as well as packaging enhancements to support shelf stability and ease of use. Firms that integrate digital tools-such as product registries, QR-coded batch verification, and digital stewardship resources-enhance trust and traceability. Overall, company strategies center on balancing clinical credibility, manufacturing excellence, and channel-specific go-to-market models to sustain competitive advantage.

Actionable recommendations for industry leaders to enhance resilience, accelerate adoption, optimize portfolios, and navigate regulatory and trade headwinds

Industry leaders should pursue a set of actionable measures to strengthen product resilience and commercial impact. First, prioritize diversification of supply sources and consider nearshoring critical manufacturing nodes to reduce exposure to international tariff shifts and logistical bottlenecks. Complement supply diversification with contractual mechanisms that allocate risk and stabilize pricing across long-term supplier agreements.

Second, accelerate formulation and packaging innovation to meet the distinct needs of companion and farm animal segments. Invest in palatable tablet technologies and stabilized liquid suspensions for clinical settings, while optimizing powder and bulk presentations for group treatments in production environments. At the same time, expand combination product development, specifically leveraging febantel with agents that address complementary parasite spectra, to simplify clinical protocols and improve adherence among end users.

Third, adapt commercial models to the realities of modern distribution. Strengthen partnerships with veterinary clinics to preserve clinical oversight, while optimizing e-commerce capabilities-both direct ecommerce and marketplace partnerships-to capture owner-initiated purchases. Tailor messaging by region and channel to reflect regulatory expectations and local usage patterns.

Finally, embed regulatory intelligence and resistance monitoring into product lifecycle planning. Proactively engage with regulatory bodies, invest in pharmacovigilance, and support stewardship programs to sustain therapeutic value and clinician confidence over time. These steps collectively position organizations to manage disruption and capitalize on clinical and commercial opportunities.

Research methodology describing data sources, analytical frameworks, validation steps, and quality controls employed to ensure robust insights into Febantel dynamics

This analysis synthesizes primary and secondary research using a structured and transparent approach. Primary inputs included interviews with practicing veterinarians, regulatory affairs specialists, distribution executives, and manufacturing operations leaders, supplemented by field-level observations of administration practices across companion and production settings. Secondary inputs were drawn from public regulatory filings, peer-reviewed clinical literature on anthelmintic efficacy and safety, trade publications, and logistics documentation relevant to pharmaceutical import/export dynamics.

Analytical frameworks encompassed segmentation analysis by animal type, distribution channel, formulation, and product type, alongside scenario-based stress testing for tariff and supply chain disruptions. Data validation relied on triangulation across independent sources and cross-checks with subject-matter experts to ensure interpretive accuracy. Quality controls included consistency reviews, plausibility checks, and sensitivity analyses to identify assumptions that materially influenced strategic implications. Ethical standards were observed throughout, with interview subjects de-identified where necessary and proprietary information handled under confidentiality protocols.

Limitations include variability in regional regulatory timelines and potential shifts in clinical practice driven by emerging resistance data, which can influence short-term adoption patterns. Nevertheless, the methodology provides a robust foundation for strategic decision-making by integrating practitioner insights with regulatory and operational perspectives.

Conclusive synthesis emphasizing strategic takeaways, future-proofing considerations, and priority actions for stakeholders engaged with Febantel in veterinary care

The synthesis underscores that febantel remains a strategically important therapeutic in veterinary parasitology, with its utility amplified through thoughtful formulation, distribution strategies, and combination therapies. Key imperatives include aligning product attributes to species-specific needs, fortifying supply chains against trade-related disruptions, and engaging proactively with regulatory and stewardship frameworks to preserve clinical efficacy. These priorities are consistent across companion and production settings, though executional emphasis differs by region and channel.

Looking ahead, stakeholders that integrate product innovation with operational agility and data-driven regulatory engagement will be best positioned to maintain clinician trust and customer access. Continued investment in combination offerings and improved formulations will support simplified protocols and higher adherence, while strategic sourcing and logistics planning will mitigate exposure to tariff-induced cost pressures. By synthesizing clinical insights with supply chain and commercial realities, organizations can convert intelligence into targeted actions that sustain the therapeutic value of febantel for diverse animal health needs.

In closing, the path forward demands coordinated efforts across R&D, manufacturing, regulatory, and commercial functions to adapt to evolving external pressures and to capitalize on opportunities presented by digital distribution and formulation innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Febantel Market, by Animal Type

  • 8.1. Companion Animal
    • 8.1.1. Cats
    • 8.1.2. Dogs
  • 8.2. Farm Animal
    • 8.2.1. Cattle
    • 8.2.2. Pigs
    • 8.2.3. Poultry
    • 8.2.4. Sheep

9. Febantel Market, by Formulation

  • 9.1. Liquid
    • 9.1.1. Solution
    • 9.1.2. Suspension
  • 9.2. Powder
  • 9.3. Tablet
    • 9.3.1. Film Coated
    • 9.3.2. Uncoated

10. Febantel Market, by Product Type

  • 10.1. Combination
    • 10.1.1. Febantel With Praziquantel
    • 10.1.2. Febantel With Pyrantel
  • 10.2. Monotherapy

11. Febantel Market, by Distribution Channel

  • 11.1. Online Retailers
    • 11.1.1. Direct Ecommerce
    • 11.1.2. Marketplaces
  • 11.2. Pharmacies
  • 11.3. Veterinary Clinics

12. Febantel Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Febantel Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Febantel Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Febantel Market

16. China Febantel Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alivira Animal Health Limited
  • 17.6. Angle Bio Pharma
  • 17.7. Jigs Chemical Limited
  • 17.8. Niksan Pharmaceutical
  • 17.9. Omshri Labs Pvt Ltd.
  • 17.10. Pranshav Health Care
  • 17.11. Pure Chem Pvt. Ltd.
  • 17.12. Raxuter Chemicals
  • 17.13. Salvavidas Pharmaceutical Pvt. Ltd.
  • 17.14. Shreeji Pharma International

LIST OF FIGURES

  • FIGURE 1. GLOBAL FEBANTEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FEBANTEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FEBANTEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FEBANTEL MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FEBANTEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FEBANTEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FEBANTEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FEBANTEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FEBANTEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FEBANTEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FEBANTEL MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FEBANTEL MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FEBANTEL MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FEBANTEL MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FEBANTEL MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FEBANTEL MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FEBANTEL MARKET SIZE, BY FARM ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FEBANTEL MARKET SIZE, BY FARM ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FEBANTEL MARKET SIZE, BY FARM ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FEBANTEL MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FEBANTEL MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FEBANTEL MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FEBANTEL MARKET SIZE, BY PIGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FEBANTEL MARKET SIZE, BY PIGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FEBANTEL MARKET SIZE, BY PIGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FEBANTEL MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FEBANTEL MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FEBANTEL MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FEBANTEL MARKET SIZE, BY SHEEP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FEBANTEL MARKET SIZE, BY SHEEP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FEBANTEL MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FEBANTEL MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FEBANTEL MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FEBANTEL MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FEBANTEL MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FEBANTEL MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FEBANTEL MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FEBANTEL MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FEBANTEL MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FEBANTEL MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FEBANTEL MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FEBANTEL MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FEBANTEL MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FEBANTEL MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FEBANTEL MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FEBANTEL MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FEBANTEL MARKET SIZE, BY FILM COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FEBANTEL MARKET SIZE, BY FILM COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FEBANTEL MARKET SIZE, BY FILM COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FEBANTEL MARKET SIZE, BY UNCOATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FEBANTEL MARKET SIZE, BY UNCOATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FEBANTEL MARKET SIZE, BY UNCOATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FEBANTEL MARKET SIZE, BY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FEBANTEL MARKET SIZE, BY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FEBANTEL MARKET SIZE, BY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FEBANTEL MARKET SIZE, BY FEBANTEL WITH PRAZIQUANTEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FEBANTEL MARKET SIZE, BY FEBANTEL WITH PRAZIQUANTEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FEBANTEL MARKET SIZE, BY FEBANTEL WITH PRAZIQUANTEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FEBANTEL MARKET SIZE, BY FEBANTEL WITH PYRANTEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FEBANTEL MARKET SIZE, BY FEBANTEL WITH PYRANTEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FEBANTEL MARKET SIZE, BY FEBANTEL WITH PYRANTEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FEBANTEL MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FEBANTEL MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FEBANTEL MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FEBANTEL MARKET SIZE, BY DIRECT ECOMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FEBANTEL MARKET SIZE, BY DIRECT ECOMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FEBANTEL MARKET SIZE, BY DIRECT ECOMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FEBANTEL MARKET SIZE, BY MARKETPLACES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FEBANTEL MARKET SIZE, BY MARKETPLACES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FEBANTEL MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FEBANTEL MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FEBANTEL MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FEBANTEL MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FEBANTEL MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FEBANTEL MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FEBANTEL MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FEBANTEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS FEBANTEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL FEBANTEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 191. GCC FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 192. GCC FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GCC FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 221. G7 FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 224. G7 FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 225. G7 FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 227. G7 FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. G7 FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 232. NATO FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 234. NATO FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 235. NATO FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 236. NATO FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. NATO FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL FEBANTEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES FEBANTEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA FEBANTEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA FEBANTEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA FEBANTEL MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA FEBANTEL MARKET SIZE, BY FARM ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA FEBANTEL MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA FEBANTEL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA FEBANTEL MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA FEBANTEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA FEBANTEL MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA FEBANTEL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA FEBANTEL MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)